292 related articles for article (PubMed ID: 31311081)
1. Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Al-Khadairi G; Decock J
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31311081
[TBL] [Abstract][Full Text] [Related]
2. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
3. The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.
Xu Y; Zou R; Wang J; Wang ZW; Zhu X
Cell Prolif; 2020 Mar; 53(3):e12770. PubMed ID: 32022332
[TBL] [Abstract][Full Text] [Related]
4. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Potential Immunotherapies Targeting PRAME in Retinoid Resistant Oral Potentially Malignant Disorders and Oral Cancer.
Dwivedi R; Mehrotra D; Chandra S; Pandey R
Curr Mol Med; 2022; 22(8):735-746. PubMed ID: 34711164
[TBL] [Abstract][Full Text] [Related]
6. The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas.
Nettersheim D; Arndt I; Sharma R; Riesenberg S; Jostes S; Schneider S; Hölzel M; Kristiansen G; Schorle H
Br J Cancer; 2016 Aug; 115(4):454-64. PubMed ID: 27441500
[TBL] [Abstract][Full Text] [Related]
7. PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.
Gelmi MC; Gezgin G; van der Velden PA; Luyten GPM; Luk SJ; Heemskerk MHM; Jager MJ
Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):36. PubMed ID: 38149971
[TBL] [Abstract][Full Text] [Related]
8. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
9. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
10. Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.
Hermes N; Kewitz S; Staege MS
Curr Cancer Drug Targets; 2016; 16(5):400-14. PubMed ID: 26694250
[TBL] [Abstract][Full Text] [Related]
11. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.
Roszik J; Wang WL; Livingston JA; Roland CL; Ravi V; Yee C; Hwu P; Futreal A; Lazar AJ; Patel SR; Conley AP
Clin Sarcoma Res; 2017; 7():11. PubMed ID: 28630682
[TBL] [Abstract][Full Text] [Related]
12. Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.
Naik A; Thomas R; Al-Khadairi G; Bacha R; Hendrickx W; Decock J
J Cell Mol Med; 2021 Nov; 25(22):10376-10388. PubMed ID: 34612587
[TBL] [Abstract][Full Text] [Related]
13.
Pankov D; Sjöström L; Kalidindi T; Lee SG; Sjöström K; Gardner R; McDevitt MR; O'Reilly R; Thorek DLJ; Larson SM; Veach D; Ulmert D
Oncotarget; 2017 Sep; 8(39):65917-65931. PubMed ID: 29029482
[TBL] [Abstract][Full Text] [Related]
14. RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors.
Wang WL; Gokgoz N; Samman B; Andrulis IL; Wunder JS; Demicco EG
Mod Pathol; 2021 May; 34(5):951-960. PubMed ID: 33009490
[TBL] [Abstract][Full Text] [Related]
15.
Lee KH; Gowrishankar K; Street J; McGuire HM; Luciani F; Hughes B; Singh M; Clancy LE; Gottlieb DJ; Micklethwaite KP; Blyth E
Clin Transl Immunology; 2020; 9(10):e1200. PubMed ID: 33101678
[TBL] [Abstract][Full Text] [Related]
16. Targeting PRAME for acute myeloid leukemia therapy.
Yang J; Chen M; Ye J; Ma H
Front Immunol; 2024; 15():1378277. PubMed ID: 38596687
[TBL] [Abstract][Full Text] [Related]
17. The PRAME family of cancer testis antigens is essential for germline development and gametogenesis†.
Kern CH; Yang M; Liu WS
Biol Reprod; 2021 Aug; 105(2):290-304. PubMed ID: 33880503
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.
Hodgson A; Jungbluth AA; Katabi N; Xu B; Downes MR
Virchows Arch; 2020 Apr; 476(4):535-542. PubMed ID: 31485721
[TBL] [Abstract][Full Text] [Related]
19. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
20. Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application.
Wei R; Dean DC; Thanindratarn P; Hornicek FJ; Guo W; Duan Z
Cancer Lett; 2020 Jun; 479():54-60. PubMed ID: 31634526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
